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INTRODUCTION
Anthracyclines are widely used in the treatment of childhood cancer.(1) However, there is clear evidence for a strong dose-dependent association between anthracyclines and congestive heart failure (CHF); it is estimated that 1 in 10 children treated with high dose anthracyclines (≥300mg/m²) will develop CHF.(2-6) Outcome following CHF is poor; 5-year survival rates are <50%. (7, 8) Detection of anthracycline-related cardiotoxicity has conventionally relied upon echocardiographic screening using resting left ventricular (LV) ejection fraction (EF) and fractional shortening (SF). (9) These parameters are derived from crude measurements of ventricular volume (EF) and size (SF), are load-dependent, may demonstrate intra-patient and inter-observer variability, and have increasingly been recognized as inadequate for detecting subtle changes in cardiac function. (9) Most importantly, at the point when changes in EF and SF are detected, functional deterioration is often irreversible, despite pharmacologic intervention. (10) Previous research on anthracycline-related cardiotoxicity has revealed that cardiac remodeling after anthracycline exposure is associated with thinning of the LV wall, enlargement of LV diameter, and subsequent increase in LV end-systolic wall stress (ESWS). (2, 4) Other than EF and SF, ESWS is the best-studied echocardiographic index in childhood cancer survivors, and is a well-recognized precursor to anthracycline-related CHF. Author Manuscript Published OnlineFirst on June 19, 2014 ; DOI: 10.1158/1078-0432.CCR- highest risk of CHF (anthracycline dose ≥300mg/m²), (1, 2, 11) and have limited the use of these indices as much-needed early and robust endpoints for secondary prevention trials.
Established blood biomarkers of acute cardiac injury (i.e. cardiac troponins) and heart failure (i.e. natriuretic peptides) have been studied in non-oncology populations, but less is known regarding their ability to detect asymptomatic LV dysfunction years after completion of cardiotoxic cancer therapy. Emerging biomarkers of cardiac dysfunction (galectin-3, protein ST-2) have not been evaluated in this population. (1, 9) The current study examined the utility and reliability of early echocardiographic indices of LV remodeling as well as blood biomarkers of cardiac injury in long-term childhood cancer survivors exposed to anthracyclines, using a recruitment strategy that enriched for patients at highest risk of CHF.
METHODS

Study Participants
Study participants included cancer survivors and healthy controls. The survivor population was recruited from patients seen between October 2010 and September 2012 at the Childhood Cancer Survivorship Clinics at City of Hope (COH) and the Children's Hospital Los Angeles (CHLA). Eligibility criteria included: 1) cancer diagnosis before 22 years of age, irrespective of current age; and 2) two or more years since completion of cancer treatment; and 3) exposure to anthracyclines. Survivors at high risk (HR: cumulative anthracycline dose ≥300mg/m²) and low risk (LR: 1-300mg/m²) of developing CHF per the Children's Oncology Group Long Term Follow-up Guidelines(14) were targeted for recruitment. We excluded survivors who were actively being treated for cardiomyopathy, as echocardiographic indices or blood biomarkers in these individuals could have been altered by pharmacologic therapy. Healthy controls without a history of cancer or cardiomyopathy were recruited from the general population, matched to HR cancer survivors on sex and age at study participation. Patient recruitment disproportionately 
Blood biomarkers
Blood samples were collected on the day of the echocardiographic assessment. Troponin-T was determined using the Elecsys 2010 system (Roche Diagnostics, Indianapolis, Indiana: Elecsys Troponin sandwich immunoassay); measurable range: 0.01 to 25.00 ng/ml. B-type natriuretic peptide (BNP) was measured using the Triage BNP test (Beckman Coulter, Fullerton, California); measurable range: 2.0 pg/mL to 5000 pg/mL. NT proBrain Natriuretic Peptide (NTproBNP) was measured using the Elecsys proBNP II test (Roche Diagnostics, Indianapolis, Indiana); lower limit of detection: 5 pg/mL. Galectin-3 was measured using a research use only assay (BG Medicine, Waltham, MA), which is a sandwich enzyme-linked immunosorbent assay (ELISA) that measures quantitative galectin-3 in plasma or serum samples; measurable range:
1.35 to 79.9 ng/mL. Protein ST2 was measured using the Presage ST2 ELISA (Critical Diagnostics, New York, NY) test; lower limit of detection: 2.0 U/mL.
Clinical data collection
Self-reported questionnaires were used to obtain baseline data on demographics. Medical 
Statistical analysis
The primary endpoint for this study was LV dysfunction, defined as abnormal ESWS (>2SD norm). ESWS was selected because of the pre-existing clinical experience with this index in anthracycline-exposed childhood cancer survivors. Median ESWS was projected to be 50±10 g/cm 2 for HC, 60±10 g/cm 2 for the LR survivors, and 70±10 g/cm 2 for HR survivors. ). Data were analyzed using SPSS Version 18.0 (IBM, Armonk, NY). All statistical tests were 2-sided, and P<0.05 were considered statistically significant.
RESULTS
Patient characteristics
Two hundred and three individuals were approached to participate in the study. One individual (HR group) refused participation, and 2 others (1 HR, 1 control) did not complete the full battery of echocardiographic and blood biomarker testing. The current report includes results from 200 study participants who completed all study measurements (participation rate: 98.5%). Table 1 summarizes the participants' characteristics. Due to previously established matching criteria, there were no statistically significant differences by sex, race/ethnicity and age at study enrollment between HR participants and healthy controls. Because of study design, HR survivors were more likely to have received a higher anthracycline dose than LR survivors. In addition, HR survivors were significantly more likely to have been treated for a non-hematologic malignancy, received chest radiation, and were older at cancer diagnosis as well as at the time of study enrollment when compared to LR survivors. There were no differences by sex, race/ethnicity, treatment era, and time from cancer diagnosis to study enrollment between the two survivor populations. Importantly, none of the survivors had clinical signs or symptoms of cardiac dysfunction at the time of study evaluation.
Echocardiographic assessment
As seen in Table 2 HCs is presented in Table 3 . All study participants had a normal EF (≥50%) at the time of study enrollment. However, HR survivors were significantly more likely to have an enlarged LV diameter in diastole/systole, as well as decreased wall-thickness in diastole/systole, resulting in a significantly decreased LV thickness-dimension ratio. In addition, median ESWS and MPI were significantly higher for HR survivors when compared to the other two populations. There were no differences in MAP, LV mass, VCFc, and indices of diastolic function such as E/A ratio, and IVRT between the three groups. 
Blood biomarkers
Candidate biomarkers of cardiac injury and remodeling were compared across all three groups (Table 1) . HR survivors had significantly higher serum NT-proBNP levels (71 pg/dL) when compared to LR survivors (37 pg/dL, p=0.02) and controls (26 pg/dL, p<0.01). There were no However, a growing concern among oncologists is whether the cardioprotective effects of these agents will interfere with the tumoricidal activity of anthracyclines. (26) This concern is especially pervasive in the pediatric oncology community where, despite data supporting the cardioprotective efficacy of dexrazoxane, the drug has yet to be incorporated as standard of care. (27) As a result, current clinical practice includes echocardiographic screening after treatment completion, and initiation of pharmacologic therapy (ACE inhibition and/or betablockade) only after abnormal EF or SF are identified. beneficial effects of these treatments in childhood cancer survivors has been shown to be short lived. (9) This is thought to be due to the progressive irreversible chronic cardiac remodeling and fibrosis which inevitably follows detectable change in EF or SF, highlighting the importance of early echocardiographic biomarkers of LV dysfunction and remodeling that precede detectable change in EF or SF.
Early intervention with afterload reduction, prior to decrease in EF or SF, has been an effective strategy for CHF risk reduction in children with progressive neuromuscular disorders such as Duchene muscular dystrophy. (22, 23) There is a paucity of information on early markers of LV dysfunction that can be used reliably in secondary prevention studies for childhood cancer survivors at high risk of CHF. To date, studies in these survivors have relied on time-and labor-intensive echocardiographic measurements to describe asymptomatic cardiac dysfunction. (11, 24, 25) These measurements have generally been obtained relatively soon after completion of cardiotoxic cancer therapy, (26, 27) and often include small numbers of survivors exposed to high anthracycline doses and therefore at the highest risk of CHF. (11, 16, 28) The current study overcomes these limitations by reporting on echocardiographic measurements that can be obtained reliably from routine 2D, M-mode, and Doppler-based echocardiograms, long after completion of cardiotoxic therapy, in a population enriched for survivors at highest risk for CHF. Overall, inter-observer correlation for these echocardiographic indices was excellent, with the highest correlation seen for LV chamber diameter in diastole (R=0.97), and the lowest for isolvolumic relaxation time (R=0.76). These findings demonstrate that despite excellent correlation across the measured indices, there may be variance in reproducibility, suggesting that certain indices are more reliably obtained than others in a multicenter setting. (29) Anthracycline cardiotoxicity is thought to be due to formation of free radicals and cardiotoxic alcohol metabolites that result in direct cardiac injury. can be especially difficult in the pediatric population due to the shortness of the neck, discomfort, and heart rate variability. Aggarwal and colleagues (17) found that substitution of MAP for carotid pulse tracing-based measurements had excellent diagnostic accuracy (sensitivity 95%, specificity 96%) for ESWS, which is the approach utilized in the current study.
We successfully obtained complete echocardiographic measurements, including ESWS, for nearly all study participants, with excellent inter-observer correlation, demonstrating clearly the feasibility of using these indices to monitor anthracycline-related LV dysfunction.
In addition to ESWS, we found a dose-dependent increase in MPI, a Doppler-derived global marker of cardiac function that is independent of heart rate, intravascular volume, and blood pressure. MPI does not rely on geometric assumptions, and has been shown to be 
Serum cardiac troponins are sensitive and specific biomarkers for cardiac cell injury, and have successfully been used to monitor cardiac injury during and shortly after anthracycline administration. (1, 9) However, in the current study, all participants were ≥2 years from exposure to cardiotoxic therapies, making it unlikely that there would be significant elevation in cardiac troponins in the setting of chronic LV dysfunction. Unlike the situation with cardiac troponins, studies have been more consistent regarding the diagnostic value of natriuretic peptides in anthracycline-related CHF monitoring.(1, 9) Several studies have documented that BNP and NT-proBNP levels, if persistently elevated, correlate well with echocardiographic indices of cardiac dysfunction. (34) (35) (36) In the current study, even though there were detectable differences in median NT-ProBNP by risk group, for the most part, the association between ESWS and natriuretic peptides (BNP, NT-ProBNP), as well as newer biomarkers such as galectin-3 and ST-2 was weak. It remains to be seen what role, if any, blood biomarkers may play in screening for cardiac dysfunction after anthracycline therapy. Current long-term follow-up guidelines for survivors of childhood cancer(9, 37) do not recommend routine surveillance using these blood biomarkers. This is largely due to the wide inter-patient variability of these biomarkers in individuals with asymptomatic LV dysfunction as measured by EF, as well as difficulties with establishment of an appropriate cutoff for abnormal values in the asymptomatic setting. (34) (35) (36) Unlike previous studies, (16, 28, 36) we did not find a significant association between anthracycline dose and spectral Doppler echocardiographic indices of LV diastolic dysfunction.
This may be because diastolic dysfunction can be transient, occurring shortly after anthracycline exposure, and is largely due to exposure of cardiac tissues to radiation.(4) Our study included survivors who were on average 12 years from diagnosis and only 10% of the population had received chest-directed radiation therapy. Lastly, there is emerging data that newer imaging modalities such as cardiac magnetic resonance imaging, "speckle tracking", and 3-D echocardiography may facilitate early identification of cardiac dysfunction prior to changes in EF. (38, 39) However, these modalities are not uniformly available across cancer follow-up 
